dromlakhani Prefer scheduled insulin therapy over noninsulin therapies for most hospitalized hyperglycemia patients
STEP 1 — Gather Information
Collect: admission diagnosis (noncritical illness), point‑of‑care glucose (>140 mg/dL defines hyperglycemia), diabetes history, home medications, renal function (eGFR), NPO status, risk factors for hypoglycemia (age >65, low BMI, CKD, prior hypoglycemia), and current insulin use.
Action: Proceed to assess eligibility for scheduled vs noninsulin therapy.
STEP 2 — Rule In / Rule Out
Is the patient hospitalized for a noncritical illness and hyperglycemic (BG >140 mg/dL)?
- Yes: Continue to classification.
- No: Consider alternative glycemic strategies or routine care.
Decision: If criteria met, move to step 3; otherwise, follow local protocols for normoglycemia or critical illness.
STEP 3 — Classify or Stratify
Does the patient have mild hyperglycemia (BG <180 mg/dL), be clinically stable, and be near discharge (expected ≤24 h) with known type 2 diabetes?
- Yes: Consider a noninsulin agent (e.g., DPP4i with correction insulin) per Recommendation 7.2.
- No: Proceed to scheduled insulin therapy.
Decision: If mild/stable/near‑discharge, evaluate noninsulin option; otherwise, schedule insulin.
STEP 4 — Decide
Initiate scheduled insulin therapy (basal‑bolus or basal plus correctional insulin) targeting glucose 100‑180 mg/dL, with point‑of‑care checks before meals and at bedtime. Adjust doses based on glucose trends and clinical status.
Action: Start scheduled insulin and monitor for hypoglycemia.
Clinical Guardrails / Mimics / Pitfalls
- Do not rely on sliding‑scale insulin alone as the sole regimen.
- Avoid metformin in eGFR <30 mL/min/1.73 m² or acute kidney injury.
- Avoid sulfonylureas due to high hypoglycemia risk in hospitalized patients.
- Avoid SGLT2 inhibitors in volume‑depleted, NPO, or hypotensive patients.
- Do not use noninsulin agents in patients with type 1 diabetes, significant hyperglycemia (>250 mg/dL), or high hypoglycemia risk.
- Never delay insulin initiation while awaiting noninsulin agent effect.
Concrete Clinical Example
A 68‑year‑old woman admitted for community‑acquired pneumonia has a random glucose of 168 mg/dL, known type 2 diabetes on metformin at home, baseline creatinine 0.9 mg/dL, and is eating regular meals. She is not near discharge. According to the algorithm, she proceeds to step 4 and receives basal‑bolus insulin (glargine 10 U nightly plus aspart 4 U TID before meals) with correctional insulin as needed.
Source: Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2022, https://doi.org/10.1210/clinem/dgac278